Stockscreener 앱 받기
3.71
0.54%
0.02
시간 외 거래:
3.72
0.01
+0.27%
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
Learn to Evaluate (BLUE) using the Charts - news.stocktradersdaily.com
Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE - ACCESS Newswire
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - BioSpace
Carlyle And Sk Capital Receive All Required Regulatory Approvals To Complete The Acquisition Of Bluebird Bio - marketscreener.com
bluebird bio nears acquisition by Carlyle and SK Capital - Investing.com
Bluebird Bio (BLUE) Nears Acquisition Completion Following Regulatory Approvals | BLUE Stock News - GuruFocus
bluebird bio Inc expected to post a loss of $3.69 a shareEarnings Preview - TradingView
Investors Who Lost Money on Bluebird Bio, Inc. (BLUE) Should Contact Levi & Korsinsky About Pending Class Action – BLUE - ACCESS Newswire
BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc.(BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE - ACCESS Newswire
Halper Sadeh LLP, bluebird bio, Inc., Walgreens Boots Alliance, Chimerix, Inc. - Olean Times Herald
Sickle Cell Disease Treatment Market Set to Witness Significant - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Cell And Gene Therapy Manufacturing Market Is Booming So Rapidly 2025-2032 -Bluebird Bio Inc., Lonza, Catalent Inc. - openPR.com
Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com
Lost Money on bluebird bio, Inc.(BLUE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire
Most US states OK Medicaid pilot for sickle cell gene therapies - The Boston Globe
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Gene Therapy For Rare Disease Market Set to Witness Significant - openPR.com
Drug and Gene Delivery Devices Market Future Business - openPR.com
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Yahoo Finance
bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - marketscreener.com
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Bluebird bio shares fall amid acquisition woes By Investing.com - Investing.com Canada
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquis - GuruFocus
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement | BLUE Stock News - GuruFocus
Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement - marketscreener.com
bluebird bio backs Carlyle and SK Capital takeover bid - Investing.com
5.73%
1.07%
자본화:
|
볼륨(24시간):